Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Beta-amyloid peptide (Aβ42) (Aβ42)
- Target
- Aβ42
- Molecular classification
- Peptide
01
Overview
Beta-amyloid peptide (Aβ42) is a 42-amino acid peptide derived from the amyloid precursor protein (APP) through sequential proteolytic cleavage by β- and γ-secretases. It is a major component of amyloid plaques in the brains of individuals with Alzheimer's disease and is considered a central factor in AD pathogenesis due to its propensity to aggregate into neurotoxic oligomers and fibrils. While it may have some physiological roles, its aggregation and plaque formation are key therapeutic targets.
- Other names
- Amyloid beta 42Abeta 42
02
Mechanism of action
Inhibition of aggregation, disruption of plaques, targeting KLVFF motif
03
Biological functions
Synaptic function (potential)Neuroprotection (potential)AggregationFibril formation
04
Disease associations
Alzheimer's diseaseNeurodegenerative disease
05
Safety considerations
Off-target effects of aggregation inhibitorsImmunogenicity of anti-Aβ antibodiesPotential for amyloid-related imaging abnormalities (ARIA) in immunotherapy
06
Biomarkers
Cerebrospinal fluid Aβ42 levelsAmyloid plaque burden (imaging)
Beyond the preview
Go deeper on Beta-amyloid peptide (Aβ42) (Aβ42).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Beta-amyloid peptide (Aβ42) (Aβ42).